Moreover, immunohistochemistry (IHC) assays showed that hepatic PCK1 protein levels were significantly lower in patients with NASH than in healthy participants (Fig. 1c). This evidence concerns the gene PCK1 and metabolic dysfunction-associated steatohepatitis.